High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma
GFL Hofbauer, A Burkhart, G Schüler… - Journal of …, 2004 - journals.lww.com
Melanoma-associated antigens are at the center of many immunotherapeutic trials in
melanoma. Little is known about the impact of antigen expression on the natural course of
disease. We stained 110 cases of primary melanoma with a median follow-up of 13 years
(range 10–18 years) for melanoma-associated antigens gp100, MelanA/MART-1, MAGE-3,
tyrosinase, and for HLA class I molecules. Of 91 cases evaluated, we found
immunoreactivity for gp100, MelanA/MART-1, and tyrosinase in 88%, 80%, and 87% of …
melanoma. Little is known about the impact of antigen expression on the natural course of
disease. We stained 110 cases of primary melanoma with a median follow-up of 13 years
(range 10–18 years) for melanoma-associated antigens gp100, MelanA/MART-1, MAGE-3,
tyrosinase, and for HLA class I molecules. Of 91 cases evaluated, we found
immunoreactivity for gp100, MelanA/MART-1, and tyrosinase in 88%, 80%, and 87% of …